Serum MicroRNA-150 Predicts Prognosis for Early-Stage Non-Small Cell Lung Cancer and Promotes Tumor Cell Proliferation by Targeting Tumor Suppressor Gene SRCIN1

Overview

Journal Clin Pharmacol Ther

Publisher Wiley

Specialty Pharmacology

Date 2017 Sep 12

PMID 28891208

Citations 18

Authors

Liren Zhang

Jing Lin

Yuanqing Ye

Taro Oba

Emanuela Gentile

Jie Lian

Jing Wang

Yang Zhao

Jian Gu

Ignacio I Wistuba

Jack A Roth

Lin Ji

Xifeng Wu

Affiliations

Soon will be listed here.

Abstract

This integrative multistage study was aimed to identify circulating microRNAs (miRNAs) as prognostic biomarkers and investigate the treatment target for early-stage non-small cell lung cancer (NSCLC) patients. In stage I-II NSCLC patients, we screened and validated the miRNA ratio signatures predictive of prognosis in serum. In tumor, we found that the expression of miR-150 in identified miRNA signatures was also associated with survival. Increased miR-150 expression promoted NSCLC cell proliferation and migration and vice versa. Specific mRNA cleavage sites targeted by endogenous miR-150 in 3' untranslated region (UTR) of SRCIN1 was identified by utilizing our recently developed novel Stem-Loop-Array reverse-transcription polymerase chain reaction (SLA-RT-PCR) assay. The blocking action of miR-150 resulted in repressed NSCLC cell growth in vitro and knockdown of miR-150 caused substantial tumor volume reduction in vivo. Our findings suggest that miR-150 binding on specific recognition sites in 3' UTR of tumor suppressor gene SRCIN1 present a potential therapeutic target for NSCLC.

Citing Articles

Circulating microRNA Panel for Prediction of Recurrence and Survival in Early-Stage Lung Adenocarcinoma.

Tai M, Bantis L, Parhy G, Kato T, Tanaka I, Chow C Int J Mol Sci. 2024; 25(4).

PMID: 38397007 PMC: 10888571. DOI: 10.3390/ijms25042331.

Silencing EGFR-upregulated expression of CD55 and CD59 activates the complement system and sensitizes lung cancer to checkpoint blockade.

Shao F, Gao Y, Wang W, He H, Xiao L, Geng X Nat Cancer. 2022; 3(10):1192-1210.

PMID: 36271172 DOI: 10.1038/s43018-022-00444-4.

Overexpression of miR-328-5p influences cell growth and migration to promote NSCLC progression by targeting LOXL4.

Ji Y, You Y, Wu Y, Wang M, He Q, Zhou X Ann Transl Med. 2022; 10(6):301.

PMID: 35433959 PMC: 9011230. DOI: 10.21037/atm-22-345.

LncRNA IGBP1-AS1 targets miR-150-5p to increase ZEB1 expression in nasopharyngeal carcinoma.

Wang L, Wang Y, Zhao Y Transl Cancer Res. 2022; 11(3):530-537.

PMID: 35402187 PMC: 8990825. DOI: 10.21037/tcr-22-291.

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer-An Update.

Kapeleris J, Warkiani M, Kulasinghe A, Vela I, Kenny L, Ladwa R Front Oncol. 2022; 12:859152.

PMID: 35372000 PMC: 8965052. DOI: 10.3389/fonc.2022.859152.

References

Wang Y, Gu J, Roth J, Hildebrandt M, Lippman S, Ye Y . Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. Cancer Res. 2013; 73(15):4801-9. PMC: 3760306. DOI: 10.1158/0008-5472.CAN-12-3273. View

Lin J, Xu K, Roth J, Ji L . Detection of siRNA-mediated target mRNA cleavage activities in human cells by a novel stem-loop array RT-PCR analysis. Biochem Biophys Rep. 2016; 6:16-23. PMC: 4776327. DOI: 10.1016/j.bbrep.2016.02.012. View

Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F . MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad Sci U S A. 2011; 108(9):3713-8. PMC: 3048155. DOI: 10.1073/pnas.1100048108. View

Chen K, Rajewsky N . The evolution of gene regulation by transcription factors and microRNAs. Nat Rev Genet. 2007; 8(2):93-103. DOI: 10.1038/nrg1990. View

Pignon J, Tribodet H, Scagliotti G, Douillard J, Shepherd F, Stephens R . Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21):3552-9. DOI: 10.1200/JCO.2007.13.9030. View

Li J, Yang H, Li Y, Liu Y, Chen S, Qi C . microRNA-146 up-regulation predicts the prognosis of non-small cell lung cancer by miRNA in situ hybridization. Exp Mol Pathol. 2014; 96(2):195-9. DOI: 10.1016/j.yexmp.2013.11.004. View

Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X . miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer. 2014; 50(5):1013-24. DOI: 10.1016/j.ejca.2013.12.024. View

Mazurenko N, Kogan E, Zborovskaya I, Kisseljov F . Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer. 1992; 28(2-3):372-7. DOI: 10.1016/s0959-8049(05)80056-5. View

Lei Z, Xu G, Wang L, Yang H, Liu X, Zhao J . MiR-142-3p represses TGF-β-induced growth inhibition through repression of TGFβR1 in non-small cell lung cancer. FASEB J. 2014; 28(6):2696-704. DOI: 10.1096/fj.13-247288. View

10.

Ji Y, Hocker J, Gattinoni L . Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Semin Immunol. 2015; 28(1):45-53. PMC: 4862908. DOI: 10.1016/j.smim.2015.11.006. View

11.

Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y . microRNA expression profile in undifferentiated gastric cancer. Int J Oncol. 2009; 34(2):537-42. View

12.

Reck M, Heigener D, Mok T, Soria J, Rabe K . Management of non-small-cell lung cancer: recent developments. Lancet. 2013; 382(9893):709-19. DOI: 10.1016/S0140-6736(13)61502-0. View

13.

Lewis B, Shih I, Jones-Rhoades M, Bartel D, Burge C . Prediction of mammalian microRNA targets. Cell. 2003; 115(7):787-98. DOI: 10.1016/s0092-8674(03)01018-3. View

14.

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

15.

Avissar M, Christensen B, Kelsey K, Marsit C . MicroRNA expression ratio is predictive of head and neck squamous cell carcinoma. Clin Cancer Res. 2009; 15(8):2850-5. PMC: 2669849. DOI: 10.1158/1078-0432.CCR-08-3131. View

16.

Katoh M, Katoh M . Evolutionary recombination hotspot around GSDML-GSDM locus is closely linked to the oncogenomic recombination hotspot around the PPP1R1B-ERBB2-GRB7 amplicon. Int J Oncol. 2004; 24(4):757-63. View

17.

Fritz H, Lindgren D, Ljungberg B, Axelson H, Dahlback B . The miR(21/10b) ratio as a prognostic marker in clear cell renal cell carcinoma. Eur J Cancer. 2014; 50(10):1758-1765. DOI: 10.1016/j.ejca.2014.03.281. View

18.

Calin G, Ferracin M, Cimmino A, Di Leva G, Shimizu M, E Wojcik S . A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med. 2005; 353(17):1793-801. DOI: 10.1056/NEJMoa050995. View

19.

McShane L, Cavenagh M, Lively T, Eberhard D, Bigbee W, Williams P . Criteria for the use of omics-based predictors in clinical trials. Nature. 2013; 502(7471):317-20. PMC: 4180668. DOI: 10.1038/nature12564. View

20.

Kelloff G, Sigman C . Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov. 2012; 11(3):201-14. DOI: 10.1038/nrd3651. View